PCSK9 Inhibitors [MoA] - N0000191730

Pharmacologic Class Information

Pharmacologic Code N0000191730
Pharmacologic Name PCSK9 Inhibitors
Pharmacologic Uses
  • PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with PCSK9 Inhibitors

The table contains 10 products whose active ingredient are classified under the same pharmacologic class PCSK9 Inhibitors [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0024-5901Praluent Non-Proprietary Name: AlirocumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5902Praluent Non-Proprietary Name: AlirocumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5903Praluent Non-Proprietary Name: AlirocumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5904Praluent Non-Proprietary Name: AlirocumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
61755-020Praluent Non-Proprietary Name: AlirocumabInjection, SolutionSubcutaneousRegeneron Pharmaceuticals, Inc.ACTIVE
61755-021Praluent Non-Proprietary Name: AlirocumabInjection, SolutionSubcutaneousRegeneron Pharmaceuticals, Inc.ACTIVE
72511-393Repatha Non-Proprietary Name: EvolocumabInjection, SolutionSubcutaneousAmgen Usa Inc.ACTIVE
72511-501Repatha Non-Proprietary Name: EvolocumabInjection, SolutionSubcutaneousAmgen Usa Inc.ACTIVE
72511-750Repatha Non-Proprietary Name: EvolocumabInjection, SolutionSubcutaneousAmgen Usa Inc.ACTIVE
72511-760Repatha Non-Proprietary Name: EvolocumabInjection, SolutionSubcutaneousAmgen Usa Inc.ACTIVE